Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
📧 Sign up to get email alerts when something new happens for Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2017-02-23Clinical Trial Update: Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab [Phase 2]
A Phase 2 trial of the complement inhibitor eculizumab for anti-neutrophil cytoplasmic antibody-associated vasculitis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-02-23Clinical Trial Update: Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens [Phase 2]
Phase 2 trial evaluating retinoids to silence autoantigens in ANCA-associated vasculitis was withdrawn.